BACKGROUND: The use of antipsychotic medications to treat aggression in youths with autism spectrum disorders (ASD) is based on open-label trials and efficacy studies. There are no studies examining the combined effectiveness of antipsychotic medications and intensive behavioral intervention (IBI) to treat aggression in ASD. METHODS: Youths with ASD and aggressive behavior received IBI. Medication use remained stable during the study period and was coded into antipsychotic, mood-stabilizing, and nonstimulant attention-deficit/hyperactivity disorder (ADHD)/sleep medication classes. Analysis of covariance (ANCOVA) and survival analyses examined the effects of medication classes on the average number of aggressive behaviors and time to behavior plan success. RESULTS: Thirty-two youths (mean age = 11.16, standard deviation [SD] = 3.31, range = 4-16 years, 75% male) with ASD received aggression reduction plans. Of these, 25 youths were taking at least one psychiatric medication (antipsychotic n = 18, mood stabilizing n = 10, and nonstimulant ADHD/sleep n = 12). Aggression dropped substantially following implementation of IBI (p < 0.001; d = 1.70). Antipsychotic medication use predicted significantly fewer sessions to achieve behavior plan success (chi(2)(1) = 5.67, p = 0.017; d = 0.93). No other medication classes influenced aggressive behavior (largest chi(2)(1) = 0.16, p = 0.694). CONCLUSIONS: Behavioral treatment combined with antipsychotic medication was the most effective approach to reducing aggressive behaviors in youths with ASD. Mood-stabilizing and nonstimulant ADHD/sleep medications did not contribute to aggression reduction.
BACKGROUND: The use of antipsychotic medications to treat aggression in youths with autism spectrum disorders (ASD) is based on open-label trials and efficacy studies. There are no studies examining the combined effectiveness of antipsychotic medications and intensive behavioral intervention (IBI) to treat aggression in ASD. METHODS: Youths with ASD and aggressive behavior received IBI. Medication use remained stable during the study period and was coded into antipsychotic, mood-stabilizing, and nonstimulant attention-deficit/hyperactivity disorder (ADHD)/sleep medication classes. Analysis of covariance (ANCOVA) and survival analyses examined the effects of medication classes on the average number of aggressive behaviors and time to behavior plan success. RESULTS: Thirty-two youths (mean age = 11.16, standard deviation [SD] = 3.31, range = 4-16 years, 75% male) with ASD received aggression reduction plans. Of these, 25 youths were taking at least one psychiatric medication (antipsychotic n = 18, mood stabilizing n = 10, and nonstimulant ADHD/sleep n = 12). Aggression dropped substantially following implementation of IBI (p < 0.001; d = 1.70). Antipsychotic medication use predicted significantly fewer sessions to achieve behavior plan success (chi(2)(1) = 5.67, p = 0.017; d = 0.93). No other medication classes influenced aggressive behavior (largest chi(2)(1) = 0.16, p = 0.694). CONCLUSIONS: Behavioral treatment combined with antipsychotic medication was the most effective approach to reducing aggressive behaviors in youths with ASD. Mood-stabilizing and nonstimulant ADHD/sleep medications did not contribute to aggression reduction.
Authors: Thomas W Frazier; Paul T Shattuck; Sarah Carter Narendorf; Benjamin P Cooper; Mary Wagner; Edward L Spitznagel Journal: J Child Adolesc Psychopharmacol Date: 2011-12-13 Impact factor: 2.576
Authors: Lawrence Scahill; Christopher J McDougle; Michael G Aman; Cynthia Johnson; Benjamin Handen; Karen Bearss; James Dziura; Eric Butter; Naomi G Swiezy; L Eugene Arnold; Kimberly A Stigler; Denis D Sukhodolsky; Luc Lecavalier; Stacie L Pozdol; Roumen Nikolov; Jill A Hollway; Patricia Korzekwa; Allison Gavaletz; Arlene E Kohn; Kathleen Koenig; Stacie Grinnon; James A Mulick; Sunkyung Yu; Benedetto Vitiello Journal: J Am Acad Child Adolesc Psychiatry Date: 2011-12-23 Impact factor: 8.829
Authors: Matthew S Goodwin; Carla A Mazefsky; Stratis Ioannidis; Deniz Erdogmus; Matthew Siegel Journal: Autism Res Date: 2019-06-21 Impact factor: 5.216
Authors: Johanna K Lake; Danica Denton; Yona Lunsky; Amy M Shui; Jeremy Veenstra-VanderWeele; Evdokia Anagnostou Journal: J Autism Dev Disord Date: 2017-05
Authors: Angele Consoli; Johan Cohen; Nicolas Bodeau; Vincent Guinchat; Lee Wachtel; David Cohen Journal: Eur Child Adolesc Psychiatry Date: 2012-08-25 Impact factor: 4.785
Authors: Lisa D Wiggins; Cy Nadler; Steven Rosenberg; Eric Moody; Nuri Reyes; Ann Reynolds; Aimee Alexander; Julie Daniels; Kathleen Thomas; Ellen Giarelli; Susan E Levy Journal: J Pediatr Date: 2021-01-22 Impact factor: 6.314